Is it ethical to have a placebo arm in reperfusion trials in the 3- to 6-hour time window? No: time frame or time gain?

Suppr

超能文献

作者信息

Köhrmann Martin, Schwab Stefan

机构信息

Department of Neurology, University Hospital Erlangen, Erlangen, Germany.

出版信息

Stroke. 2009 Apr;40(4):1543-4. doi: 10.1161/STROKEAHA.108.520676. Epub 2009 Mar 12.

DOI:10.1161/STROKEAHA.108.520676

PMID:19286606

Abstract

摘要

相似文献

Is it ethical to have a placebo arm in reperfusion trials in the 3- to 6-hour time window? No: time frame or time gain?

Stroke. 2009 Apr;40(4):1543-4. doi: 10.1161/STROKEAHA.108.520676. Epub 2009 Mar 12.

Is it ethical to have a placebo arm in reperfusion trials in the 3- to 6-hour time window? Yes.

Stroke. 2009 Apr;40(4):1541-2. doi: 10.1161/STROKEAHA.108.532234. Epub 2009 Mar 12.

Ethics and feasibility of placebo-controlled interventional acute stroke trials.

Stroke. 2009 Sep;40(9):e533-4; discussion e535-8. doi: 10.1161/STROKEAHA.109.553214. Epub 2009 Jul 23.

The ethics of thrombolytic trials beyond 3 (or 4.5) hours: randomized controlled trials are required to change clinical practice.

Stroke. 2009 Apr;40(4):1545. doi: 10.1161/STROKEAHA.108.520684. Epub 2009 Mar 12.

Life after DIAS II.

Int J Stroke. 2007 Nov;2(4):236-7. doi: 10.1111/j.1747-4949.2007.00158.x.

Clinical judgment and deep value commitments.

Am J Bioeth. 2011 Feb;11(2):18-9. doi: 10.1080/15265161.2010.540066.

4.5 hours: the new time window for tissue plasminogen activator in stroke.

Stroke. 2009 Jun;40(6):2266-7. doi: 10.1161/STROKEAHA.108.544171. Epub 2009 Apr 30.

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Stroke. 2005 Jan;36(1):66-73. doi: 10.1161/01.STR.0000149938.08731.2c. Epub 2004 Nov 29.

There is sufficient evidence to support intra-arterial therapy of ischemic stroke.

J Neurointerv Surg. 2012 May;4(3):167-8. doi: 10.1136/neurintsurg-2012-010336. Epub 2012 Mar 17.

Intra-arterial therapies for acute ischemic stroke: unsafe and without proven value.

J Neurointerv Surg. 2012 May;4(3):164-6. doi: 10.1136/neurintsurg-2012-010338. Epub 2012 Mar 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Is it ethical to have a placebo arm in reperfusion trials in the 3- to 6-hour time window? No: time frame or time gain?

Stroke. 2009 Apr;40(4):1543-4. doi: 10.1161/STROKEAHA.108.520676. Epub 2009 Mar 12.

Is it ethical to have a placebo arm in reperfusion trials in the 3- to 6-hour time window? Yes.

Stroke. 2009 Apr;40(4):1541-2. doi: 10.1161/STROKEAHA.108.532234. Epub 2009 Mar 12.

Ethics and feasibility of placebo-controlled interventional acute stroke trials.

Stroke. 2009 Sep;40(9):e533-4; discussion e535-8. doi: 10.1161/STROKEAHA.109.553214. Epub 2009 Jul 23.

The ethics of thrombolytic trials beyond 3 (or 4.5) hours: randomized controlled trials are required to change clinical practice.

Stroke. 2009 Apr;40(4):1545. doi: 10.1161/STROKEAHA.108.520684. Epub 2009 Mar 12.

Life after DIAS II.

Int J Stroke. 2007 Nov;2(4):236-7. doi: 10.1111/j.1747-4949.2007.00158.x.

Clinical judgment and deep value commitments.

Am J Bioeth. 2011 Feb;11(2):18-9. doi: 10.1080/15265161.2010.540066.

4.5 hours: the new time window for tissue plasminogen activator in stroke.

Stroke. 2009 Jun;40(6):2266-7. doi: 10.1161/STROKEAHA.108.544171. Epub 2009 Apr 30.

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Stroke. 2005 Jan;36(1):66-73. doi: 10.1161/01.STR.0000149938.08731.2c. Epub 2004 Nov 29.

There is sufficient evidence to support intra-arterial therapy of ischemic stroke.

J Neurointerv Surg. 2012 May;4(3):167-8. doi: 10.1136/neurintsurg-2012-010336. Epub 2012 Mar 17.

Intra-arterial therapies for acute ischemic stroke: unsafe and without proven value.

J Neurointerv Surg. 2012 May;4(3):164-6. doi: 10.1136/neurintsurg-2012-010338. Epub 2012 Mar 17.